Scott K Pruitt

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells
    Scott K Pruitt
    Durham VA Medical Center, Durham, NC, USA
    Eur J Immunol 41:3553-63. 2011
  2. ncbi request reprint Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses
    Zeinab Abdel-Wahab
    Department of Surgery, Duke University, Durham, NC 27710, USA
    J Surg Res 124:264-73. 2005
  3. doi request reprint Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy
    Christina K Augustine
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Mol Cancer Ther 9:2090-101. 2010
  4. ncbi request reprint Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine
    Tomio Ueno
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, NC 27710, USA
    Mol Cancer Ther 5:732-8. 2006
  5. ncbi request reprint Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity
    Matthew F Kalady
    Department of Surgery, Duke University Medical Center and Durham VA Medical Center, Durham, North Carolina 27710, USA
    J Surg Res 116:24-31. 2004
  6. doi request reprint Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma
    Hiroaki Toshimitsu
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    Ann Surg Oncol 17:2247-54. 2010
  7. ncbi request reprint Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity
    Sae Hee Ko
    Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:289-97. 2006
  8. pmc Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
    Jens Dannull
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Invest 123:3135-45. 2013
  9. ncbi request reprint Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution
    Zeinab Abdel-Wahab
    Department of Surgery, Duke University Medical Center, P O Box 2624 MSRB, Durham, NC 27710, USA
    Cell Immunol 224:86-97. 2003
  10. pmc Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy
    April K S Salama
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    PLoS ONE 8:e57665. 2013

Collaborators

Detail Information

Publications30

  1. pmc Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells
    Scott K Pruitt
    Durham VA Medical Center, Durham, NC, USA
    Eur J Immunol 41:3553-63. 2011
    ..Based on these results, this approach of using local delivery of immune modulators to enhance vaccine-induced immunity is currently being evaluated in a phase I clinical cancer immunotherapy trial...
  2. ncbi request reprint Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses
    Zeinab Abdel-Wahab
    Department of Surgery, Duke University, Durham, NC 27710, USA
    J Surg Res 124:264-73. 2005
    ..Cotransfection of dendritic cells (DC) with MART-1 and constitutively active TLR4 (caTLR4) RNA enhances the maturation of DC...
  3. doi request reprint Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy
    Christina K Augustine
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Mol Cancer Ther 9:2090-101. 2010
    ..These results show that sorafenib in combination with chemotherapy provides a novel approach to enhance chemotherapeutic efficacy in the regional treatment of in-transit melanoma...
  4. ncbi request reprint Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine
    Tomio Ueno
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, NC 27710, USA
    Mol Cancer Ther 5:732-8. 2006
    ..Clinical trials using chemotherapy modulation may improve response rates in future regional infusion and perfusion drug trials...
  5. ncbi request reprint Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity
    Matthew F Kalady
    Department of Surgery, Duke University Medical Center and Durham VA Medical Center, Durham, North Carolina 27710, USA
    J Surg Res 116:24-31. 2004
    ....
  6. doi request reprint Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma
    Hiroaki Toshimitsu
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    Ann Surg Oncol 17:2247-54. 2010
    ..The goal of this study was to determine if a systemically administered PARP-inhibitor (INO-1001) could augment the efficacy of TMZ in a rat model of extremity malignant melanoma...
  7. ncbi request reprint Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity
    Sae Hee Ko
    Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:289-97. 2006
    ..The aim of this study was to determine whether hyperthermia could further augment the efficacy of temozolomide, an alkylating agent, against melanoma and improve its therapeutic index in a rat model of isolated limb infusion...
  8. pmc Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
    Jens Dannull
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Invest 123:3135-45. 2013
    ..Since proteasomes generate peptides presented by HLA class I molecules, we hypothesized that mature melanoma antigen-loaded DCs engineered to process antigens through cPs would be superior inducers of antimelanoma immunity in vivo...
  9. ncbi request reprint Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution
    Zeinab Abdel-Wahab
    Department of Surgery, Duke University Medical Center, P O Box 2624 MSRB, Durham, NC 27710, USA
    Cell Immunol 224:86-97. 2003
    ..The ease with which such a mutation can be made in RNA presents another potential advantage of using RNA for immunotherapy. Our results support considering this strategy for enhancing the immunogenicity of DC-based RNA vaccines...
  10. pmc Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy
    April K S Salama
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    PLoS ONE 8:e57665. 2013
    ..The objectives of this study were to identify patterns of metastatic recurrence, to determine the influence of metastatic site on survival, and to identify high-risk periods for recurrence...
  11. ncbi request reprint Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4
    Robin M Cisco
    Department of Surgery, Duke University and Durham Veterans Affairs Medical Centers, Durham, NC 27710, USA
    J Immunol 172:7162-8. 2004
    ....
  12. ncbi request reprint In-transit melanoma: the role of alkylating-agent resistance in regional therapy
    Elizabeth G Grubbs
    Department of General Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Surg 199:419-27. 2004
    ....
  13. pmc Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution
    Amanda K Raymond
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Surg 213:306-16. 2011
    ..Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) are used to manage advanced extremity melanoma, but no consensus exists as to which treatment is preferable and how to monitor patients post-treatment...
  14. pmc Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion
    Gina Shetty
    Department of Immunology, Duke University, Durham, NC, USA
    Ann Surg Oncol 20:1128-35. 2013
    ....
  15. ncbi request reprint Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity
    Jens Dannull
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Blood 110:4341-50. 2007
    ..This alteration of DC proteasome composition, which enhances the ability of mature antigen-loaded DCs to stimulate anti-tumor immune responses, may lead to more effective DC-based tumor immunotherapy...
  16. ncbi request reprint Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents
    Yasunori Yoshimoto
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, NC 27710, USA
    Mol Cancer Ther 6:1492-500. 2007
    ..Our observations also point out the limited ability of analysis of the GST/glutathione pathway to predict response to chemotherapies like melphalan whose resistance is primarily mediated through a complex mechanism of detoxification...
  17. ncbi request reprint Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma
    Tomio Ueno
    Department of Surgery, Box 3118 Medical Center, Duke University Medical Center, Durham, NC 27710, USA
    Am J Surg 188:532-7. 2004
    ..Regional infusion therapy with melphalan (LPAM) is an accepted treatment for advanced extremity melanoma. However, much room exists for improving the therapeutic index of this type of therapy...
  18. doi request reprint A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US
    Georgia M Beasley
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Surg 208:706-15; discussion 715-7. 2009
    ..Establishing response and toxicity to ILI as compared with hyperthermic isolated limb perfusion is important for optimizing future regional chemotherapeutic strategies in melanoma...
  19. ncbi request reprint CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy
    Mark W Onaitis
    Department of Surgery, Duke University and Durham VA Medical Centers, Durham, NC 27710, USA
    Surgery 134:300-5. 2003
    ..This study evaluated the effects of exogenous soluble CD40 ligand (sCD40L) on RNA-transfected DC preparations and their subsequent ability to generate antimelanoma cytolytic T cells...
  20. ncbi request reprint Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer
    Elizabeth G Grubbs
    Department of General Surgery, Duke University Medical Center, Durham, North Carolina, 27710, USA
    Ann Surg Oncol 13:1645-54. 2006
    ..Real-time quantitative polymerase chain reaction (qPCR) may prove to be a sensitive technique by which to evaluate potential tumor markers in pancreatic cancer...
  21. doi request reprint Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion
    Georgia M Beasley
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, NC 27710, USA
    Ann Surg Oncol 15:2195-205. 2008
    ..This study examined the efficacy and toxicity of ILI, compared to hyperthermic isolated limb perfusion (HILP), in treating extremity in-transit melanoma...
  22. ncbi request reprint Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells
    Matthew F Kalady
    Department of General Surgery, Duke University and Durham VA Medical Centers, Durham, North Carolina 27710, USA
    J Gastrointest Surg 8:175-81; discussion 181-2. 2004
    ..These data suggest that total tumor RNA-pulsed dendritic cells may have potential as an adjuvant immunotherapy for patients with pancreatic cancer...
  23. pmc Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model
    Chunrui Tan
    Division of Otolaryngology, Duke University Medical Center, Durham, NC, USA
    J Transl Med 11:148. 2013
    ....
  24. pmc Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function
    Jens Dannull
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Blood 119:3113-22. 2012
    ..Collectively, our data suggest that LTC(4) represents a promising candidate to replace PGE(2) in DC maturation protocols for cancer vaccination...
  25. doi request reprint Sentinel node biopsy for head and neck melanoma: a systematic review
    Nicole de Rosa
    Duke University, Durham, NC, USA
    Otolaryngol Head Neck Surg 145:375-82. 2011
    ..This systematic review was conducted to examine the test performance of sentinel node biopsy in head and neck melanoma, including the identification rate and false-negative rate...
  26. ncbi request reprint The role of hyperthermia in regional alkylating agent chemotherapy
    Omar I Abdel-Wahab
    Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA
    Clin Cancer Res 10:5919-29. 2004
    ..These data indicate a synergistic cytotoxic effect of l-phenylalanine mustard + hyperthermia in isolated limb infusion, which is not attributable to enhanced tumor drug uptake...
  27. doi request reprint Pediatric melanoma: a single-institution experience of 150 patients
    Jennifer H Aldrink
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Pediatr Surg 44:1514-21. 2009
    ..Despite guidelines describing clinical features and histopathologic criteria to distinguish these lesions, misdiagnoses still occur. We report our experience over 30 years in a pediatric population with malignant melanoma...
  28. ncbi request reprint Modulation of resistance to regional chemotherapy in the extremity melanoma model
    Elizabeth G Grubbs
    Departments of General Surgery, Internal Medicine, and Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Surgery 136:210-8. 2004
    ..This study explored systemic modulation of resistance in conjunction with intra-arterial regional therapy to determine if tumor responses to melphalan could be improved with acceptable toxicity...
  29. doi request reprint The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost
    April K S Salama
    Duke Comprehensive Cancer Center, Duke University Medical Center DUMC, Durham, North Carolina 27710, USA
    Cancer Invest 30:637-41. 2012
    ..Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients...
  30. ncbi request reprint Enhanced dendritic cell antigen presentation in RNA-based immunotherapy
    Matthew F Kalady
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Surg Res 105:17-24. 2002
    ....